stockrow
Saturday 7 November 2026
Export PRME’s income statement to Excel — free account
Prime Medicine, Inc.
PRME Healthcare Biotechnology
Prime Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.6 million, up 55.3% from fiscal 2024.
- Revenue
- +3.50%
- EPS
- +41.5%
- Free cash flow
- +4.40%
Quarter to June 2026, against a year earlier
4.61
0.16
+3.60%
Follow PRME
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 5 | — | — | — | 3 | 5 | 4 | (2.3%) | 9 | 11 | 16 | +51.2% | |
| Gross margin, % | — | — | — | — | 100.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | (3) | (2) | (166) | (123) | (198) | (196) | (201) | (188) | +107.4% | ||||||
| EBT margin, % | — | — | — | 0.00 | (29.62) | 0.00 | 0.00 | 0.00 | (6,566.61) | (4,342.44) | (4,613.11) | (4,342.4) pt | ||||||
| Net income | — | — | — | (3) | (3) | (165) | (122) | (198) | (196) | (201) | (188) | +107.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 1.97 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.02 | n/m | |||||
| Earnings | — | — | — | (0.03) | (1.91) | (14.19) | (4.19) | (2.18) | (1.65) | (1.35) | (1.10) | +88.6% | ||||||
| Cash flow | — | — | — | (0.01) | (2.10) | (2.63) | (3.89) | (1.82) | (1.04) | (1.09) | (0.88) | +107.0% | ||||||
| Capex | — | — | — | 0.00 | (0.24) | (0.32) | (0.47) | (0.10) | (0.06) | (0.03) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.01) | (2.34) | (2.95) | (4.36) | (1.91) | (1.10) | (1.12) | (0.88) | +107.9% | ||||||
| Book value | — | — | — | 0.00 | 0.00 | 18.47 | 9.33 | 1.46 | 1.29 | 0.81 | 0.22 | n/m | ||||||
| Shares, m | — | — | — | 96 | 3 | 13 | 34 | 91 | 119 | 149 | 166 | +7.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | — | — | — | 0.00 | 111.44 | 200.59 | 37.1 | ||||||
| P/B | — | — | — | — | 0.00 | — | — | — | 2.26 | 4.27 | 20.52 | 2.2 | ||||||
| EV/Sales | — | — | — | — | 0.00 | — | — | — | 0.00 | 73.08 | 177.25 | 24.4 | ||||||
| EV/FCF | — | — | — | — | (1.55) | — | — | — | (1.20) | (2.03) | (4.60) | (1.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (6) | (34) | (132) | (165) | (123) | (163) | (156) | +122.7% | |||||
| Capex | — | — | — | — | (1) | (4) | (16) | (9) | (7) | (5) | (1) | +48.0% | ||||||
| Free cash flow | — | — | — | (1) | (6) | (38) | (148) | (174) | (130) | (167) | (157) | +123.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 34 | 213 | 270 | 87 | 174 | 144 | 65 | +33.5% | |||||
| Net debt | — | — | — | — | (53) | (270) | (294) | (122) | (190) | (178) | (95) | +27.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | 240 | 316 | 133 | 153 | 121 | 40 | (15.7%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | 0.00 | (121.99) | (42.89) | (71.51) | (79.73) | (62.83) | (71.16) | (62.8) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (325.92) | (1,122.17) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 0.00 | 0.00 | 239.27 | (177.48) | (88.19) | (136.88) | (146.81) | (373.29) | (146.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 150 | 175 | 234 | 214 | 146 | — | (0.7%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026
Prime Medicine, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience, Inc. | $858.2M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| RIGL Rigel Pharmaceuticals, Inc. | $853.9M | 2.4× | 16.4× | +16.45% (above 0%: growing) | −54.84% (below 0%: shrinking) | +43.90% (above 0%: growing) | 86.67% | 21.15% | Compare |
| SNDX Syndax Pharmaceuticals, Inc. | $843.6M | — (loss-making) | — (loss-making) | +81.59% (above 0%: growing) | n/m | +61.43% (above 0%: growing) | 83.20% | (50.30%) | Compare |
| AKTS Aktis Oncology, Inc. | $826.0M | — (loss-making) | — (loss-making) | — | n/m | −12.77% (below 0%: shrinking) | 100.00% | (853.99%) | Compare |
| CRVS Corvus Pharmaceuticals, Inc. | $818.5M | — (loss-making) | — | — | n/m | −171.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MGTX MeiraGTx Holdings PLC | $817.3M | 11.8× | 30.3× | +8,608.59% (above 0%: growing) | n/m | +13.06% (above 0%: growing) | 97.77% | 76.04% | Compare |
| PRME Prime Medicine, Inc. | $807.1M | — (loss-making) | — (loss-making) | +3.50% (above 0%: growing) | n/m | +4.40% (above 0%: growing) | 100.00% | (3,750.87%) | |
| ALMS Alumis Inc. | $780.9M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | Compare |
| ANNX Annexon, Inc. | $759.3M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $822.2M | — | — | +49.02% | — | +0.14% | 86.67% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Ownership
Directors and executive officers, together
16.04%
David Liu
11.26%
Robert Nelsen
10.29%
Entities affiliated with ARCH Venture Partners
10.24%
Entities affiliated with GV
9.17%
Bristol-Myers Squibb Company
6.09%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement